ps-15 and Malaria

ps-15 has been researched along with Malaria* in 3 studies

Other Studies

3 other study(ies) available for ps-15 and Malaria

ArticleYear
Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials.
    Journal of medicinal chemistry, 2001, Nov-08, Volume: 44, Issue:23

    A total of 34 analogues of the biguanide PS-15 (5s), a prodrug of the diaminotriazine WR-99210 (8s), have been prepared. Several of them, such as 5b (PS-33) and 5m (PS-26), maintain or exceed the in vivo activity of PS-15 while not requiring the use of highly regulated starting materials. The putative diaminotriazine metabolites of these new analogues (compounds 8) have also been prepared and shown to maintain the activity against resistant P. falciparum strains. The structure-activity relationships of biguanides 5 and putative metabolites 8 are discussed.

    Topics: Animals; Antimalarials; Drug Evaluation, Preclinical; Female; Folic Acid Antagonists; Guanidines; Malaria; Male; Mice; Plasmodium berghei; Plasmodium falciparum; Prodrugs; Proguanil; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Triazines

2001
In vitro activities of the biguanide PS-15 and its metabolite, WR99210, against cycloguanil-resistant Plasmodium falciparum isolates from Thailand.
    Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:10

    The in vitro activities of the new biguanide PS-15 and its putative active metabolite, WR99210, were determined against seven different isolates or clones of Plasmodium falciparum. The mean 50% inhibitory concentrations of PS-15 and WR99210 were 1,015 and 0.06 ng/ml, respectively. WR99210 was up to 363 times more potent than cycloguanil, the active metabolite of proguanil, against cycloguanil-resistant parasites. The pronounced activity of WR99210 against multidrug-resistant P. falciparum indicates that further studies are required to determine the value of the prodrug, PS-15, as an antimalarial agent.

    Topics: Animals; Antimalarials; Drug Resistance, Microbial; Folic Acid Antagonists; Malaria; Plasmodium falciparum; Prodrugs; Proguanil; Saimiri; Thailand; Triazines

1997
Evaluation of WR250417 (a proguanil analog) for causal prophylactic activity in the Plasmodium cynomolgi-Macaca mulatta model.
    The American journal of tropical medicine and hygiene, 1994, Volume: 50, Issue:2

    The Plasmodium cynomolgi-Macaca mulatta model has been used to test the antimalarial activity of new drugs for both radical cure and casual prophylaxis. The proguanil analog WR250417 (also known as PS-15) was evaluated for causal prophylactic activity in rhesus monkeys infected with P. cynomolgi bastianelli. Four monkeys were orally dosed with 40 mg/kg/day of WR250417 over three days (-1, 0, and +1). Sporozoite-induced infection of P. cynomolgi was initiated on day 0 with 1 x 10(6) sporozoites to each monkey. Compound WR250417 extended the prepatent period from an average of 8.5 days for controls (n = 2) to a mean of 18.3 days (range 18-19 days, n = 4) for drug-treated monkeys. Analysis of plasma drug concentrations by high-performance liquid chromatography showed that the monkeys converted the WR250417 to its putative principal active metabolite WR99210 (a dihydrotriazine). These findings demonstrate that WR250417 and its principal metabolite do not prevent primary infection by P. cynomolgi.

    Topics: Administration, Oral; Animals; Antimalarials; Chromatography, High Pressure Liquid; Disease Models, Animal; Female; Half-Life; Macaca mulatta; Malaria; Male; Plasmodium cynomolgi; Proguanil; Triazines

1994